HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 55.74M | 55.50M | 55.85M | 56.42M | 56.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.74M | 55.50M | 55.85M | 56.42M | 56.77M |
| Cost of Revenue | 16.15M | 15.79M | 15.74M | 15.60M | 15.46M |
| Gross Profit | 39.59M | 39.71M | 40.11M | 40.82M | 41.31M |
| SG&A Expenses | 21.73M | 22.00M | 22.96M | 24.20M | 25.57M |
| Depreciation & Amortization | 21.99M | 21.82M | 21.79M | 21.79M | 22.16M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.87M | 59.61M | 60.49M | 61.58M | 63.18M |
| Operating Income | -4.13M | -4.11M | -4.64M | -5.16M | -6.41M |
| Income Before Tax | -10.71M | -12.88M | -13.83M | -14.80M | -13.91M |
| Income Tax Expenses | -420.00K | -445.00K | 287.00K | 245.00K | 4.08M |
| Earnings from Continuing Operations | -10.29 | -12.43 | -14.12 | -15.04 | -17.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.29M | -12.43M | -14.12M | -15.04M | -17.99M |
| EBIT | -4.13M | -4.11M | -4.64M | -5.16M | -6.41M |
| EBITDA | 17.35M | 17.19M | 16.67M | 16.15M | 15.27M |
| EPS Basic | -0.32 | -0.39 | -0.45 | -0.48 | -0.57 |
| Normalized Basic EPS | -0.21 | -0.25 | -0.28 | -0.29 | -0.34 |
| EPS Diluted | -0.33 | -0.39 | -0.46 | -0.49 | -0.58 |
| Normalized Diluted EPS | -0.21 | -0.25 | -0.28 | -0.29 | -0.34 |
| Average Basic Shares Outstanding | 127.69M | 128.21M | 125.07M | 125.46M | 125.53M |
| Average Diluted Shares Outstanding | 127.69M | 128.21M | 125.07M | 125.46M | 125.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |